Entos Pharmaceuticals’ Post

Entos Pharmaceuticals and its partner, Aegis Life, Inc. announced the first participant has been dosed in the phase 1/2 clinical trial evaluating Covigenix VAX-002 as a COVID-19 booster vaccine. We're excited to announce the first patient dosed in the phase 1/2 trial of our COVID-19 DNA vaccine booster candidate,” said John Lewis , CEO, Entos Pharmaceuticals. “This milestone brings us closer to providing protection against the still-emerging SARS-CoV-2 omicron variants to people in North America, as well as developing countries in need of fridge-stable vaccines. Read More: https://lnkd.in/dz5fbCDB “This phase 1/2 trial is important because it tests a new method of delivering protection against the virus that causes COVID-19,” said Jean-François Roussy, principal investigator at Diex Recherche. #mededgemea #COVID19 #BoosterVaccine #EntosPharmaceuticals #VaccineResearch #PublicHealth #COVID19Updates #VaccineDevelopment Steve C.